Related Experiment Video
Updated: Aug 5, 2026

An IL-8 Transiently Transgenized Mouse Model for the In Vivo Long-term Monitoring of Inflammatory Responses
Published on: July 7, 2017
Interleukin 13-Induced Inflammation Increases DPP4 Abundance but Does Not Enhance Middle East Respiratory Syndrome
Kun Li1, Jennifer A Bartlett1, Christine L Wohlford-Lenane1
1Department of Pediatrics, Pappajohn Biomedical Institute, Carver College of Medicine, University of Iowa, Iowa City, IA.
Background:
Chronic pulmonary conditions such as asthma and chronic obstructive pulmonary disease increase the risk of morbidity and mortality during infection with the Middle East respiratory syndrome coronavirus (MERS-CoV). We hypothesized that individuals with such comorbidities are more susceptible to MERS-CoV infection due to increased expression of its receptor, dipeptidyl peptidase 4 (DPP4).
Methods:
We modeled chronic airway disease by treating primary human airway epithelia with the Th2 cytokine interleukin 13 (IL-13), examining how this affected DPP4 protein levels with MERS-CoV entry and replication.
Results:
IL-13 exposure for 3 days led to greater DPP4 protein abundance, while a 21-day treatment raised DPP4 levels and caused goblet cell metaplasia. Surprisingly, despite this increase in receptor availability, MERS-CoV entry and replication were not significantly affected by IL-13 treatment.
Conclusions:
Our results suggest that greater DPP4 abundance is likely not the primary mechanism leading to increased MERS severity in the setting of Th2 inflammation. Transcriptional profiling analysis highlighted the complexity of IL-13-induced changes in airway epithelia, including altered expression of genes involved in innate immunity, antiviral responses, and maintenance of the extracellular mucus barrier. These data suggest that additional factors likely interact with DPP4 abundance to determine MERS-CoV infection outcomes.
Insights
Individuals with chronic lung conditions like asthma may not be more susceptible to Middle East respiratory syndrome coronavirus (MERS-CoV) due to increased DPP4 receptor levels. Other factors likely influence MERS-CoV infection severity.
Area of Science:
- Virology
- Immunology
- Pulmonology
Background:
- Chronic pulmonary conditions, including asthma and COPD, elevate MERS-CoV morbidity and mortality risks.
- Increased expression of the MERS-CoV receptor, dipeptidyl peptidase 4 (DPP4), was hypothesized as a cause for heightened susceptibility.
Purpose of the Study:
- To investigate the impact of Th2 inflammation, mimicking chronic airway disease, on DPP4 expression and MERS-CoV susceptibility.
- To determine if elevated DPP4 levels in airway epithelia influence MERS-CoV entry and replication.
Main Methods:
- Primary human airway epithelia were treated with the Th2 cytokine IL-13 to model chronic airway disease.
- DPP4 protein levels, MERS-CoV entry, and replication were assessed following IL-13 exposure.
- Goblet cell metaplasia and transcriptional changes were analyzed.
Main Results:
- Short-term (3-day) IL-13 exposure increased DPP4 protein abundance.
- Long-term (21-day) IL-13 treatment elevated DPP4 levels and induced goblet cell metaplasia.
- Despite increased DPP4, MERS-CoV entry and replication were not significantly affected by IL-13 treatment.
Conclusions:
- Elevated DPP4 levels alone do not appear to be the primary driver of increased MERS severity in Th2-inflamed airways.
- IL-13 significantly alters gene expression in airway epithelia, impacting innate immunity and antiviral responses.
- Complex interactions between DPP4 abundance and other factors likely dictate MERS-CoV infection outcomes.
More Related Videos
09:02Infection of Primary Nasal Epithelial Cells Grown at an Air-Liquid Interface to Characterize Human Coronavirus-Host Interactions
Published on: September 22, 2023
10:21Author Spotlight: Exploring the Role of Inflammation in the Co-occurrence of Primary Sjogren's Syndrome and Lung Adenocarcinoma
Published on: September 20, 2024
Related Concept Videos
Diphtheria
Type I Diabetes II: Pathophysiology
Chronic Obstructive Pulmonary Disease III: Chronic Bronchitis Features
Inflammatory Bowel Disease III: Crohn's Disease
Chronic Pancreatitis I: Introduction
Chronic Pancreatitis II: Pathophysiology